Asia FX dithers as dollar steadies before Powell speech; yen muted after CPI data
On Thursday, Citizens JMP reiterated its Market Outperform rating and $81.00 price target for Rhythm Pharmaceuticals (NASDAQ:RYTM), following insights from a leading endocrinologist. The target sits within the broader analyst range of $60-94, with InvestingPro data showing four analysts recently revising their earnings estimates upward for the upcoming period. Dr. Lewis (JO:LEWJ) Blevins, an expert in the field, expressed his optimism regarding the potential of Rhythm’s setmelanotide for treating hypothalamic obesity (HO). According to the analyst’s report, Dr. Blevins believes that the drug’s efficacy in Phase 3 trials could be significant, even if it only halts weight gain in patients, with any weight loss seen as an additional benefit.
Dr. Blevins, who is not privy to the specific outcomes of the ongoing trials, suggested that setmelanotide could become a standard treatment for HO if it gains approval. Given the prevalence of the condition in his practice, he anticipates becoming the leading prescriber of setmelanotide for HO in the United States. The market appears to share this optimism, with Rhythm’s revenue growing 68% year-over-year and maintaining impressive gross profit margins of nearly 90%.
The analyst’s confidence in Rhythm Pharmaceuticals is supported by a risk-adjusted, discounted cash flow (DCF) analysis, which underpins the $81.00 price target. This valuation reflects the anticipated success of setmelanotide in clinical trials and its potential market impact.
Rhythm Pharmaceuticals is currently engaged in Phase 3 trials for setmelanotide, a treatment designed to address the underlying causes of genetic obesity disorders, including HO. The company’s commitment to developing therapies for rare genetic disorders of obesity positions it at the forefront of this specialized medical field.
The reiterated rating and price target by Citizens JMP highlight the positive outlook for Rhythm Pharmaceuticals as it continues to make strides in its clinical developments. With a strong current ratio of 3.24 and a market capitalization of $3.43 billion, the company appears well-positioned to fund its development pipeline. Investors and industry watchers will be closely monitoring the progress of setmelanotide trials and the potential for it to meet the treatment needs of HO patients as outlined by Dr. Blevins. For deeper insights into Rhythm’s financial health and growth potential, including exclusive ProTips and comprehensive valuation metrics, visit InvestingPro.
In other recent news, Rhythm Pharmaceuticals has been active with several significant developments. The company recently announced it has regained the rights to its obesity drug, IMCIVREE® (setmelanotide), in mainland China, Hong Kong, and Macau, following the termination of a licensing agreement with RareStone Group Ltd. This move aligns with Rhythm’s strategy to expand the global availability of setmelanotide. Additionally, Rhythm Pharmaceuticals received orphan drug designation in Japan for setmelanotide, aimed at treating acquired hypothalamic obesity, a rare condition characterized by excessive weight gain and insatiable hunger. This designation highlights the significant medical need for treatments targeting this condition in Japan.
Analyst firms have also weighed in on Rhythm Pharmaceuticals’ potential. H.C. Wainwright reaffirmed its Buy rating and $70 price target, emphasizing the company’s progress and potential in addressing unmet medical needs. Similarly, Needham raised its price target for Rhythm Pharmaceuticals to $66, maintaining a Buy rating, with optimism surrounding the upcoming Phase 3 trial results for setmelanotide. Stifel also reiterated a Buy rating with a $78 price target, expressing confidence in the company’s management and the potential revenue opportunities for setmelanotide and other next-generation treatments. These developments and analyst insights underscore the growing anticipation for Rhythm Pharmaceuticals’ upcoming clinical trial results and its broader strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.